Stocks · News reference
Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it has entered into an exclusive global licensing
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Alector, Inc. reported its third-quarter 2026 financial results, highlighting a net income of $124.6 million driven by the recognition of deferred revenue following the termination of its agreement with GSK.
Filed: 2026-10-16 AccNo: 0001193125-26-424204 Size: 423 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.
HC Wainwright & Co. analyst Andrew S. Fein maintains Alector (NASDAQ:ALEC) with a Buy and raises the price target from $5 to $8.
Morgan Stanley analyst Sean Laaman maintains Alector (NASDAQ:ALEC) with a Underweight and raises the price target from $2 to $3.